Exploring ovarian cancer, biomarkers HRD & RB1, and how Labcorp innovations are advancing precision oncology.
In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with colleague and pathologist Dr. Kyle Strickland to explore the complexities of ovarian cancer and the evolving science shaping its diagnosis and treatment.
Together, they discuss how ovarian cancer is often misunderstood as a single disease, the importance of accurately classifying its subtypes, and the critical role biomarkers like HRD and RB1 play in improving outcomes. Dr. Strickland shares his latest research on RB1, explains how HRD testing is reshaping patient care, and highlights Labcorp’s advancements with OmniSeq Insight, designed to provide clinicians with deeper insights into tumor biology. Listeners will gain a clearer understanding of how these scientific developments are transforming precision oncology and opening the door to new possibilities for ovarian cancer patients.
Tune in to the full conversation now.
Follow Us
Presented by Labcorp Oncology
www.oncology.labcorp.com